Business Wire

Cognite Appoints Four Global Leaders to Fuel Market Momentum

Share

Cognite, a global leader in industrial software, today announced four appointments to lead the company’s scaling efforts for its next stage of growth. Cognite's new executive leaders are Moe Tanabian, Chief Product Officer (CPO); Paul Lightfoot, SVP of User Experience; Emmanuelle Camus, President of Cognite EMEA; and Liat Berger, Chief Human Resources Officer (CHRO). These leaders held roles of increasing responsibility at Red Hat, Microsoft, Amazon, PTC, and Aker Solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230109005470/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

L-R Liat Berger, CHRO; Moe Tanabian, CPO; Emmanuelle Camus, President EMEA; Paul Lightfoot, SVP UX (Photo: Business Wire)

Cognite’s CEO Girish Rishi said, "Building a high-performance team and developing our talent is a top priority. I'm pleased to welcome these leaders with diverse, global experiences, including deep technical skill sets and tenures at Fortune 500 companies. These accomplished executives will help us further scale our commitments to customers and partners as we solve the industrial data availability-to-value problem together."

Moe Tanabian, Cognite’s new Chief Product Officer, is charged with product strategy and execution, as well as product management, design, and engineering. He has been driving innovation at scale for nearly three decades, particularly in the areas of software products, AI, ML, and IoT. Tanabian recently served as Vice President and General Manager of Azure Light Edge for Microsoft, driving more than $2 billion P&L for Microsoft's portfolio of products in IoT, OT, and embedded industrial domains. Prior to his role at Microsoft, Tanabian worked for Samsung as Vice President of Smart Products and IoT, as well as Amazon, where he led the efforts to build and deliver the Amazon Android Appstore on Kindle Fire and Amazon Phone devices. Tanabian holds a master’s degree in Systems and Computer Engineering from Carleton University, Ottawa, Ontario and an MBA from the School of Business Queen’s University, Kingston, Ontario.

Liat Berger will serve as the new CHRO. She has a demonstrated track record of HR leadership with global multi-site companies and will help drive Cognite’s scale-up strategy. She has spent the last ten years at Aker Solutions and most recently served as Senior Vice President of People and Organization, Corporate, where she focused on business strategy by helping leaders identify, prioritize and build organizational capabilities, behaviors, and structures needed to support the change agenda. She also served as the Head of P&O for the Subsea Organization at Aker Solutions, which was composed of 4,500 employees distributed in 10 different locations on four different continents. Her expertise is building and balancing global companies while incorporating local realities, and she will play a key role in energizing Cognite’s global workforce. She is a graduate in Business Administration of Universidade Federal do Parana and has a specialization in Group Dynamics and People Management.

Emmanuelle Camus will assume the role of President of Cognite EMEA. She will focus on accelerating Cognite’s growth and strengthening the company’s position as a leading industrial software provider in the EMEA region in the Energy, Power, and Clean Tech and Manufacturing markets. Prior to joining Cognite, Camus spent 25 years at PTC in various leadership roles focused on business transformation and served most recently as their Senior Vice President of Alliances EMEAI. She has extensive experience in driving exponential growth in Europe & India through B2B sales and leveraging strategic alliances & partners and a strong background in solving Industry 4.0 challenges, digital transformation, Corporate Social Responsibility and Diversity, Equality & Inclusion. She is a graduate of NEOMA Business School.

Paul Lightfoot will support Tanabian as the new Senior Vice President of User Experience as Cognite doubles down on product design to allow customers to exponentially grow the number of data-literate industrial subject matter experts within their organizations. In his role, Lightfoot will lead Cognite's product design vision and strategy to meet these evolving needs as the OT industry is now being software-defined and is evolving into the fusing of physical and digital worlds at scale. Previously, he held product design leadership roles at several high-growth technology companies, most recently building out the product design/user experience practice at Red Hat as its Global Director, User Experience Product Design Team. Paul brings his passion for nurturing and developing a customer-obsessed culture to the role, as well as product management leadership and a focus on the discovery and development of product-market-fit. Paul has a degree in Management Information Systems from Bridgewater State University.

About Cognite

Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-heavy industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michelle Holford
Vice President of Public Relations, Cognite
Michelle.Holford@Cognite.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye